Myositis is a group of rare autoimmune diseases that cause chronic inflammation and weakness in the skeletal muscles. It affects roughly 2 to 25 people per 100,000, and while it can strike at any age, different forms tend to appear at different life stages. The immune system mistakenly attacks healthy muscle fibers, leading to progressive weakness that can interfere with everyday movements like climbing stairs, lifting objects, or even swallowing.
The Main Types of Myositis
Myositis isn’t a single disease. It’s an umbrella term for several distinct conditions, each with its own pattern of symptoms and complications. The three most common forms in adults are dermatomyositis, polymyositis, and inclusion body myositis. Children most often develop juvenile dermatomyositis.
A newer category, immune-mediated necrotizing myopathy, is now recognized as a separate subtype. It tends to cause especially severe muscle damage with very high levels of muscle enzymes in the blood, sometimes 50 times the normal range. Some patients also have a form called amyopathic dermatomyositis, where the characteristic skin rashes appear without significant muscle weakness.
How It Feels: Weakness and Skin Changes
The hallmark of most forms of myositis is weakness in the muscles closest to the trunk of the body. The five weakest muscle groups are typically the hip flexors, hip extensors, hip abductors, neck flexors, and shoulder abductors. In practical terms, this means difficulty getting up from a chair, climbing stairs, reaching overhead, or holding your head up. The lower body and proximal muscles (those near the center of the body) are hit harder than the hands and feet.
Polymyositis tends to cause more pronounced leg weakness than dermatomyositis, particularly in the hips, knees, and ankles. Inclusion body myositis follows a different pattern: it typically affects people over 50, progresses slowly, and often targets the finger flexors and quadriceps, which can make gripping objects and walking increasingly difficult.
Dermatomyositis adds a layer of distinctive skin involvement. The heliotrope rash is a violet or reddish discoloration of the upper eyelids, sometimes with swelling. Gottron papules are raised, reddish patches over the knuckles. The “shawl sign” describes redness across the upper back, shoulders, and neck, while the “V sign” refers to a similar rash on the front of the neck and upper chest. These skin changes can appear before, during, or after muscle weakness develops.
What Causes the Muscle Damage
In myositis, the immune system turns against muscle tissue through several overlapping mechanisms. In polymyositis and inclusion body myositis, specialized immune cells called cytotoxic T cells invade non-damaged muscle fibers and directly attack them. These T cells release toxic molecules (perforin and granzyme B) that punch holes in muscle cell membranes. Making matters worse, some of these invading T cells are resistant to the normal signals that would tell them to stop, which is why the inflammation can persist even during treatment.
Muscle cells in all forms of myositis also display abnormally high levels of a surface marker that essentially flags them as targets for immune attack. This triggers stress inside the cells themselves, damaging their internal protein-processing machinery and generating free radicals that directly weaken the fibers. In dermatomyositis specifically, high levels of a signaling molecule called type 1 interferon damage the small blood vessels supplying the muscles, cutting off their energy supply and causing a characteristic pattern of muscle fiber death around the edges of muscle bundles.
How Myositis Is Diagnosed
Diagnosis typically involves a combination of blood tests, physical examination, and sometimes a muscle biopsy. One of the first clues is an elevated level of creatine kinase (CK) in the blood, an enzyme released when muscle fibers are damaged. In polymyositis and dermatomyositis, CK levels are often 10 to 50 times the upper limit of normal. Necrotizing myopathy can push levels even higher. Inclusion body myositis usually produces more modest elevations, no greater than about 12 times normal. Importantly, 5 to 10% of patients with dermatomyositis or polymyositis have normal CK levels, often because the muscles have already atrophied significantly.
Blood tests for myositis-specific antibodies have become increasingly important for pinpointing the exact subtype. Anti-Jo-1 antibodies, the most common of the anti-synthetase antibodies, point toward a form associated with joint inflammation, lung disease, and cracked “mechanic’s hands.” Anti-Mi-2 antibodies are linked to classic dermatomyositis with prominent skin findings and strong muscle involvement. Anti-SRP antibodies signal a rapidly progressive, severe form of necrotizing myopathy. Anti-MDA5 antibodies are associated with minimal muscle involvement but carry a high risk of aggressive lung disease.
The international classification criteria developed by EULAR and ACR use a scoring system that combines clinical features and, when available, biopsy findings. A score corresponding to at least a 55% probability of inflammatory myopathy is considered sufficient for a “probable” diagnosis, with sensitivity of 87% and specificity of 82% without biopsy data. Adding biopsy results pushes those numbers to 93% and 88%.
Lung Disease and Other Complications
Interstitial lung disease is the most common and most serious complication, affecting 40 to 50% of all myositis patients. It ranges from mild and slowly progressive to life-threatening. In patients with anti-synthetase syndrome or anti-MDA5 dermatomyositis, the prevalence climbs to around 90%. The chronic form generally responds well to treatment, with five-year survival rates of 80 to 90%. The rapidly progressive form, especially with anti-MDA5 antibodies, can be much harder to control.
Difficulty swallowing (dysphagia) is another significant concern, particularly in inclusion body myositis and in patients with certain antibody profiles. Weakness in the throat muscles can lead to choking, aspiration, and nutritional problems. Some forms of dermatomyositis, particularly those associated with anti-TIF1γ or anti-NXP2 antibodies, carry an increased risk of underlying cancer, which is why screening is part of the workup for newly diagnosed adults.
Treatment: Medications and Timeline
For most forms of myositis, treatment starts with high-dose corticosteroids to rapidly suppress inflammation. In severe cases, this may begin with intravenous pulses over three consecutive days. The higher dose is typically maintained for two to four weeks, then gradually reduced by 20 to 25% each month until reaching a low maintenance dose. The goal is to control the disease while minimizing the significant side effects of long-term steroid use.
Because steroids alone rarely keep myositis in check long-term, most patients also start a steroid-sparing immunosuppressive medication early on. Methotrexate and azathioprine are the most common first choices for muscle involvement. Other options include calcineurin inhibitors and, for resistant cases, intravenous immunoglobulin or cyclophosphamide. The specific combination depends heavily on the myositis subtype, antibody profile, and which organs are involved.
Inclusion body myositis is the notable exception. It responds poorly to immunosuppressive therapy, and no medication has been proven to slow its progression reliably. Management focuses on maintaining function through exercise and adaptive strategies.
The Role of Exercise
Exercise was once thought to be harmful in myositis, but research over the past two decades has shown the opposite. All studies to date report that exercise is safe across all types and stages of the disease. It’s now considered a core part of treatment alongside medication.
The recommended approach is to start at low intensity under the guidance of a physical therapist, with follow-up at least every three months during the first year. Exercise should begin within weeks of starting medical treatment, not delayed until the disease is fully controlled. A home exercise program at low to moderate intensity, adapted to individual disease activity and disability, is well tolerated by patients with recent-onset disease. As strength and stamina improve, the program is gradually progressed. For patients with established, stable polymyositis or dermatomyositis, research supports intensive programs including 30 minutes of stationary cycling at 70% of maximum aerobic capacity combined with resistance training, three days a week for 12 weeks.
For inclusion body myositis, where medications offer limited benefit, regular exercise is especially important. Evidence shows it can help maintain muscle function, while inactivity accelerates decline.